JP2023500045A - Ｓｔｉｎｇアゴニストを用いたがんを処置する方法 - Google Patents

Ｓｔｉｎｇアゴニストを用いたがんを処置する方法 Download PDF

Info

Publication number
JP2023500045A
JP2023500045A JP2022522274A JP2022522274A JP2023500045A JP 2023500045 A JP2023500045 A JP 2023500045A JP 2022522274 A JP2022522274 A JP 2022522274A JP 2022522274 A JP2022522274 A JP 2022522274A JP 2023500045 A JP2023500045 A JP 2023500045A
Authority
JP
Japan
Prior art keywords
compound
administered
dose
immune checkpoint
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500045A5 (https=
Inventor
チェン、ジージェン
サン、リジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023500045A publication Critical patent/JP2023500045A/ja
Publication of JP2023500045A5 publication Critical patent/JP2023500045A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022522274A 2019-10-14 2020-10-14 Ｓｔｉｎｇアゴニストを用いたがんを処置する方法 Pending JP2023500045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914881P 2019-10-14 2019-10-14
US62/914,881 2019-10-14
PCT/US2020/055633 WO2021076666A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Publications (2)

Publication Number Publication Date
JP2023500045A true JP2023500045A (ja) 2023-01-04
JP2023500045A5 JP2023500045A5 (https=) 2023-10-19

Family

ID=73060121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522274A Pending JP2023500045A (ja) 2019-10-14 2020-10-14 Ｓｔｉｎｇアゴニストを用いたがんを処置する方法

Country Status (7)

Country Link
US (1) US20230270773A1 (https=)
EP (1) EP4045059A1 (https=)
JP (1) JP2023500045A (https=)
CN (1) CN114929241A (https=)
AU (1) AU2020366354A1 (https=)
CA (1) CA3157849A1 (https=)
WO (1) WO2021076666A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014110A (es) * 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
JP2019509339A (ja) * 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509339A (ja) * 2016-03-18 2019-04-04 イミューン センサー リミテッド ライアビリティ カンパニー 環状ジヌクレオチド化合物および使用方法
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOTHERAPY CANCER, vol. 2 (Suppl.3), JPN6024037188, 2014, pages 158, ISSN: 0005567680 *

Also Published As

Publication number Publication date
WO2021076666A1 (en) 2021-04-22
EP4045059A1 (en) 2022-08-24
AU2020366354A1 (en) 2022-03-17
CN114929241A (zh) 2022-08-19
CA3157849A1 (en) 2021-04-22
US20230270773A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
JP7160345B2 (ja) がんの治療のための組合せ調製物
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
JP2011511072A5 (https=)
RU2471483C2 (ru) Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан
Xiang et al. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer
JP2026503515A (ja) 非ホジキンリンパ腫治療用医薬組成物及びその使用
JP2023533111A (ja) 免疫チェックポイント阻害剤とのｓｔｉｎｇアゴニスト併用治療
JP2023500045A (ja) Ｓｔｉｎｇアゴニストを用いたがんを処置する方法
US20230121320A1 (en) Sting agonist combination treatments with cytokines
JP2022551672A (ja) 乳癌治療法
AU715260B2 (en) TNF receptor and steroid hormone in a combined therapy
AU2005311191A1 (en) Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives
HK40076423A (en) Methods of treating cancer with a sting agonist
US12240904B2 (en) Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
HK40087098A (zh) Sting激动剂与免疫检查点抑制剂的联合治疗
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
Yang et al. EXTH-77. POLIO VIROTHERAPY OF MURINE BRAIN TUMORS INDUCES MICROGLIA PROLIFERATION AND INFLAMMATION THAT IS POTENTIATED BY IMMUNE CHECKPOINT BLOCKADE
WO2021224381A1 (en) Combination therapy for treating cancer
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
Rahman et al. EXTH-79. TRIAL WORKING GROUPS TO EXPEDITE PRECLINICAL TRANSLATION FOR PAEDIATRIC BRAIN TUMOURS
KR20220140723A (ko) 암의 치료를 위한 약제학적 조합
Wu AB0390 Efficacy and safety of yisaipu, a recombinant human tumor necrosis factor-α receptor II IGG FC fusion protein in chinese patients with moderate to severe rheumatoid arthritis
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408